This was Citius second try for FDA approval, after the regulator rejected Lymphir in July 2023, outlining the need for enhanced product resting requirements. In its resubmitted data package, the company included findings from the from the Phase III Study 302 trial, where treatment with the drug led to an objective response rate of 36.2%, with 8.7% reaching complete response
Generic Akkermansia products may use different strains with uncharacterized metabolite profiles
Working with healthcare professionals can help individuals identify the most sustainable and affordable treatment plan
10.1007/s13346-024-01576-z
BPC-157 has emerged as one of the most promising peptides for Achilles tendon recovery in runners
In the matched cohort, which controlled for potential confounding factors, GLP-1 use was associated with a 30.5% reduction in breast cancer incidence